Acalabrutinib Vs Zanubrutinib For Relapsed/Refractory CLL | Adam Kittai, MD | ASCO 2023 

Interview with Adam Kittai, MD from The Ohio State University Comprehensive Cancer Center
at ASCO 2023. Filmed June 3rd, 2023.
Dr. Kittai discusses a comparative study between acalabrutinib and zanubrutinib in the treatment of relapsed refractory CLL. The study aims to address the lack of head-to-head comparisons between these second-generation BTK inhibitors. By performing a meta-analysis, the presenter compares the ASCEND study with the Alpine study to assess efficacy and safety outcomes. The analysis reveals similar efficacy between the two drugs and suggests a slightly improved safety profile for acalabrutinib in terms of hypertension and hemorrhage. While the findings are hypothesis-generating, Dr. Kittai emphasizes the need for a phase three randomized controlled trial for definitive conclusions.
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtree.org/campaign/...
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree.org/